MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling

Molecular Psychiatry

Volumn 23, Issue 4, 2018, Pages 1051-1065

  Mellios, N ^a,b   Feldman, D A ^b   Sheridan, S D ^b,c   Ip, J P K ^b   Kwok, S ^b   Amoah, S K ^a   Rosen, B ^b   Rodriguez, B A ^a   Crawford, B ^b   Swaminathan, R ^a   Chou, S ^b   Li, Y ^d   Ziats, M ^e   Ernst, C ^f   Jaenisch, R ^d   Haggarty, S J ^c   Sur, M ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN 2; MICRORNA; MICRORNA 199; MICRORNA 214; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; MECP2 PROTEIN, HUMAN; MECP2 PROTEIN, MOUSE; MIRN199 MICRORNA, HUMAN; MIRN214 MICRORNA, HUMAN; SMALL INTERFERING RNA;

AKT SIGNALING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; EMBRYO; ENZYME ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; MAPK SIGNALING; MOUSE; NERVE CELL; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; ORGANOID; PRIORITY JOURNAL; ANIMAL; BRAIN; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; EMBRYOLOGY; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETT SYNDROME; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; CELL DIFFERENTIATION; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MAP KINASE SIGNALING SYSTEM; METHYL-CPG-BINDING PROTEIN 2; MICE; MICRORNAS; NEUROGENESIS; NEURONS; PROTO-ONCOGENE PROTEINS C-AKT; RETT SYNDROME; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 85044285349     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.86     Document Type: Article

References (74)

1. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
2. Coolen M, Bally-Cuif L. MicroRNAs in brain development and physiology. Curr Opin Neurobiol 2009; 19: 461-470.
3. Mellios N, Sur M. The emerging role of microRNAs in schizophrenia and autism spectrum disorders. Front Psychiatry 2012; 3: 39.
4. Mellios N, Sugihara H, Castro J, Banerjee A, Le C, Kumar A et al. miR-132, an experience-dependent microRNA, is essential for visual cortex plasticity. Nat Neurosci 2011; 14: 1240-1242.
5. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpGbinding protein 2. Nat Genet 1999; 23: 185-188.
6. Castro J, Mellios N, Sur M. Mechanisms and therapeutic challenges in autism spectrum disorders: insights from Rett syndrome. Curr Opin Neurol 2013; 26: 154-159.
7. Cheng TL, Wang Z, Liao Q, Zhu Y, Zhou WH, Xu W et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev Cell 2014; 28: 547-560.
8. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 2010; 189: 127-141.
9. Urdinguio RG, Fernandez AF, Lopez-Nieva P, Rossi S, Huertas D, Kulis M et al. Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics 2010; 5: 656-663.
10. Wu H, Tao J, Chen PJ, Shahab A, Ge W, Hart RP et al. Genome-wide analysis reveals methyl-CpG-binding protein 2-dependent regulation of microRNAs in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 2010; 107: 18161-18166.
11. Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist 2004; 10: 118-128.
12. Einspieler C, Kerr AM, Prechtl HF. Is the early development of girls with Rett disorder really normal? Pediatr Res 2005; 57: 696-700.
13. Kerr AM. Early clinical signs in the Rett disorder. Neuropediatrics 1995; 26: 67-71.
14. Schanen NC, Kurczynski TW, Brunelle D, Woodcock MM, Dure LSt, Percy AK. Neonatal encephalopathy in two boys in families with recurrent Rett syndrome. J Child Neurol 1998; 13: 229-231.
15. Trappe R, Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 2001; 68: 1093-1101.
16. Castro J, Garcia RI, Kwok S, Banerjee A, Petravicz J, Woodson J et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci USA 2014; 111: 9941-9946.
17. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci USA 2007; 104: 1931-1936.
18. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007; 315: 1143-1147.
19. Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci USA 2014; 111: 4596-4601.
20. Mellios N, Woodson J, Garcia RI, Crawford B, Sharma J, Sheridan SD et al. beta2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 2014; 111: 9947-9952.
21. Fukuda T, Itoh M, Ichikawa T, Washiyama K, Goto Y. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol 2005; 64: 537-544.
22. Kishi N, Macklis JD. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 2004; 27: 306-321.
23. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue-and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002; 11: 115-124.
24. Armstrong DD, Deguchi K, Antallfy B. Survey of MeCP2 in the Rett syndrome and the non-Rett syndrome brain. J Child Neurol 2003; 18: 683-687.
25. Petazzi P, Akizu N, Garcia A, Estaras C, Martinez de Paz A, Rodriguez-Paredes M et al. An increase in MECP2 dosage impairs neural tube formation. Neurobiol Dis 2014; 67: 49-56.
26. Tsujimura K, Abematsu M, Kohyama J, Namihira M, Nakashima K. Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2. Exp Neurol 2009; 219: 104-111.
27. Bedogni F, Cobolli Gigli C, Pozzi D, Rossi RL, Scaramuzza L, Rossetti G et al. Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms. Cereb Cortex 2016; 26: 2517-2529.
28. Farra N, Zhang WB, Pasceri P, Eubanks JH, Salter MW, Ellis J. Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol Psychiatry 2012; 17: 1261-1271.
29. Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci USA 2011; 108: 14169-14174.
30. Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Loven J et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 2013; 13: 446-458.
31. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143: 527-539.
32. Williams EC, Zhong X, Mohamed A, Li R, Liu Y, Dong Q et al. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet 2014; 23: 2968-2980.
33. Fernandes TG, Duarte ST, Ghazvini M, Gaspar C, Santos DC, Porteira AR et al. Neural commitment of human pluripotent stem cells under defined conditions recapitulates neural development and generates patient-specific neural cells. Biotechnol J 2015; 10: 1578-1588.
34. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451: 141-146.
35. Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 2011; 6: e26203.
36. Abraham S, Sheridan SD, Laurent LC, Albert K, Stubban C, Ulitsky I et al. Propagation of human embryonic and induced pluripotent stem cells in an indirect co-culture system. Biochem Biophys Res Commun 2010; 393: 211-216.
37. Sheridan SD, Surampudi V, Rao RR. Analysis of embryoid bodies derived from human induced pluripotent stem cells as a means to assess pluripotency. Stem Cells Int 2012; 2012: 738910.
38. Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 2012; 15: 477-486, S471.
39. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME et al. Cerebral organoids model human brain development and microcephaly. Nature 2013; 501: 373-379.
40. Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA, Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res 2009; 37: 123-128.
41. Florio M, Huttner WB. Neural progenitors, neurogenesis and the evolution of the neocortex. Development 2014; 141: 2182-2194.
42. Englund C, Fink A, Lau C, Pham D, Daza RA, Bulfone A et al. Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex. J Neurosci 2005; 25: 247-251.
43. Cobos I, Calcagnotto ME, Vilaythong AJ, Thwin MT, Noebels JL, Baraban SC et al. Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy. Nat Neurosci 2005; 8: 1059-1068.
44. Penna E, Orso F, Taverna D. miR-214 as a key hub that controls cancer networks: small player, multiple functions. J Invest Dermatol 2015; 135: 960-969.
45. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243.
46. Pucilowska J, Puzerey PA, Karlo JC, Galan RF, Landreth GE. Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facialcutaneous and related syndromes. J Neurosci 2012; 32: 8663-8677.
47. Samuels IS, Karlo JC, Faruzzi AN, Pickering K, Herrup K, Sweatt JD et al. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci 2008; 28: 6983-6995.
48. Zhang J, Shemezis JR, McQuinn ER, Wang J, Sverdlov M, Chenn A. AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development. Neural Dev 2013; 8: 7.
49. Gonzales ML, LaSalle JM. The role of MeCP2 in brain development and neurodevelopmental disorders. Curr Psychiatry Rep 2010; 12: 127-134.
50. Hammer S, Dorrani N, Dragich J, Kudo S, Schanen C. The phenotypic consequences of MECP2 mutations extend beyond Rett syndrome. Ment Retard Dev Disabil Res Rev 2002; 8: 94-98.
51. Akbarian S, Chen RZ, Gribnau J, Rasmussen TP, Fong H, Jaenisch R et al. Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis 2001; 8: 784-791.
52. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001; 27: 327-331.
53. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001; 27: 322-326.
54. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA 2004; 101: 6033-6038.
55. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006; 49: 341-348.
56. Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci 2007; 27: 10912-10917.
57. Schmid DA, Yang T, Ogier M, Adams I, Mirakhur Y, Wang Q et al. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J Neurosci 2012; 32: 1803-1810.
58. Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 2009; 106: 2029-2034.
59. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454: 56-61.
60. Bauman ML, Kemper TL, Arin DM. Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. Neurology 1995; 45: 1581-1586.
61. Armstrong DD. Rett syndrome neuropathology review 2000. Brain Dev 2001; 23 (Suppl 1): S72-S76.
62. Armstrong D, Dunn JK, Antalffy B, Trivedi R. Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol 1995; 54: 195-201.
63. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell 2015; 162: 375-390.
64. Ariani F, Hayek G, Rondinella D, Artuso R, Mencarelli MA, Spanhol-Rosseto A et al. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet 2008; 83: 89-93.
65. Ito-Ishida A, Ure K, Chen H, Swann JW, Zoghbi HY. Loss of MeCP2 in parvalbuminand somatostatin-expressing neurons in mice leads to distinct Rett syndrome-like phenotypes. Neuron 2015; 88: 651-658.
66. Selvamani A, Sathyan P, Miranda RC, Sohrabji F. An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS ONE 2012; 7: e32662.
67. Cimadamore F, Amador-Arjona A, Chen C, Huang CT, Terskikh AV. SOX2-LIN28/let-7 pathway regulates proliferation and neurogenesis in neural precursors. Proc Natl Acad Sci USA 2013; 110: E3017-E3026.
68. Tsujimura K, Irie K, Nakashima H, Egashira Y, Fukao Y, Fujiwara M et al. miR-199a links MeCP2 with mTOR signaling and its dysregulation leads to Rett syndrome phenotypes. Cell Rep 2015; 12: 1887-1901.
69. del Gaudio D, Fang P, Scaglia F, Ward PA, Craigen WJ, Glaze DG et al. Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet Med 2006; 8: 784-792.
70. Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 2005; 77: 442-453.
71. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007; 10: 1513-1514.
72. Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 2011; 20: 1182-1196.
73. Casanova EL, Casanova MF. Genetics studies indicate that neural induction and early neuronal maturation are disturbed in autism. Front Cell Neurosci 2014; 8: 397.
74. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 2013; 154: 518-529.